Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate to severe non-malignant pain and opioid induced constipation: a UK cost-utility analysis

Dunlop, William, Uhl, Reiner, Khan, Iftekhar, Taylor, Anna and Barton, Garry ORCID: https://orcid.org/0000-0001-9040-011X (2012) Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate to severe non-malignant pain and opioid induced constipation: a UK cost-utility analysis. Journal of Medical Economics, 15. pp. 564-575. ISSN 1941-837X

Full text not available from this repository. (Request a copy)

Abstract

Objective: To compare the cost effectiveness of prolonged release oxycodone/naloxone (OXN) tablets (Targinact) and prolonged release oxycodone (OXY) tablets (OxyContin) in patients with moderate-to-severe non-malignant pain and opioid-induced constipation (OIC) from the perspective of the UK healthcare system.

Item Type:	Article
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Health Economics Faculty of Medicine and Health Sciences > Research Groups > Health Services and Primary Care Faculty of Medicine and Health Sciences > Research Groups > Norwich Clinical Trials Unit Faculty of Medicine and Health Sciences > Research Groups > Public Health and Health Services Research (former - to 2023) Faculty of Medicine and Health Sciences > Research Centres > Population Health (former - to 2025) Faculty of Medicine and Health Sciences > Research Centres > Public Health
Depositing User:	Julie Frith
Date Deposited:	09 Apr 2013 13:26
Last Modified:	18 Jun 2026 14:43
URI:	https://ueaeprints.uea.ac.uk/id/eprint/42096
DOI:	10.3111/13696998.2012.665279

Actions (login required)

View Item